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The Long-Term Efficacy of Multivisceral Transplantation 
J.R. Madariaga, J. Reyes, G. Mazariegos, J.J. Fung, T.E. Starzl, and K. Abu-Elmagd 
UNDER tacrolimus-based immunosuppression. long-
term rehabilitation has become achievable with in-
testinal transplantation. I Herein. we report our 9-year 
experience with multivisceral transplantation for patients 
with diffuse irreversible gastrointestinal diseases. 
MATERIALS AND METHODS 
Between May 2. 1990 and August 18. 1999. a total of 135 intestinal 
transplants were performed at our center. Of these. 18 (13%) were 
multiviseeraL which included stomach. duodenum. pancreas. and 
intestine. The liver was part of the graft in all but three cases and 
donor colon was included in 10 (56%). Nine were adults and 10 
were females. Of the 18 grafts. 15 were primary. and the indications 
for transplantation were dysmotility syndrome (35%). splanchnic 
thrombosis (24%). gut neoplasm (18%). and others (24%). Before 
transplantation. mean (:':SD) bilirubin was II :': 16 mgldL and 
mean number of abdominal operations was 2.2 :': 1.2. and most 
patients received TPN for a mean period of 29 :': 19 months. 
All donors were cadaveric and ABO identical with random HLA 
match. and no attempts were made to immunomodulate the graft. 
Lymphocytotoxic crossmatch was positive in two (11 %) patients. 
and 44% of the donors were cytomegalovirus (CMV) positive. The 
mean cold ischemia time was 8.5 :!: 1.7 hours. and the operative 
time was 13.8 :!: 3.3 hours. The details of the donor and recipient 
operations have been described elsewhere.2•3 Tacrolimus and ste-
roids were the baseline immunosuppression for all patients. Imuran 
or Cellcept were used from the outset as a third drug in selected 
cases. Cytoxan or Daclizumab were used as induction therapy for a 
few cases. Unmodified donor bone marrow cells were infused 
perioperatively as a single dose (3 to 5 x 10" cell/kg body weight) 
in three (17%) recipients. The postoperative management protocol 
was described elsewhere. l .4 and follow-up was to October 30. 1999 
with a minimum of 3 and maximum of 98 months. 
RESULTS 
Using the Kaplan-Meier method. the actuarial patient and 
graft survival rates were 54% and 42% at 1 and 5 years, 
respectively. The survival rates were similar between adults 
and children. The leading causes of patient death and graft 
loss were microbial/viral infections (54%), posttransplant 
lymphoproliferative disease (PTLD) (38%), and rejection 
(8%). The lethal infections were CMV (n = 1), adenovirus 
(n = 1). fungal (n = 2). bacterial (n = 1), and de novo 
C-hepatitis (n = 1). Inclusion of the colon was associated 
with high (90%) mortality. 
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With a mean follow-up of 30 months. the incidence of 
allograft rejection was 66% for intestine. 27% for liver, 20% 
for colon. 11 % for stomach. and 11 % for pancreas. OKT3 
was used to treat steroid-resistant rejection in 39% of 
recipients. There was no single example of vascular or 
chronic rejection. 
The major morbid events were CMV disease (35%), 
PTLD (47%). and graft-versus-host disease (GVHD) (6%). 
With equal frequency of CMV disease among adults and 
children. PTLD occurred at a higher rate among the 
pediatric recipients. The diagnosis of GVHD was unequiv-
ocal in only one adult recipient that evolved to chronic 
disease. Of the 18 grafts, 12 (67%) were fully functioning 
and recipients were completely off total parenteral nutrition 
(TPN) at the time of patient death or last follow-up. All of 
the current survivors are free of TPN with full enteric 
nutritional autonomy with four recipients beyond the 3-year 
milestone after transplantation. 
DISCUSSION 
Multivisceral transplantation has become a viable rescue 
therapy for patients with diffuse irreversible gastrointestinal 
diseases. The most common indications in adults were total 
occlusion of the splanchnic circulation, particularly of the 
portomesenteric system associated with liver failure, and/or 
intractable intestinal variceal bleeding. Dysmotility and 
malabsorption syndromes were more common indications 
among the pediatric patients. The type of graft was tailored 
according to the need of each individual recipient. 
Compared to isolated intestinal allografts. the incidence 
of refractory rejection was lower and the rate of lethal 
infections. particularly PTLD, was higher among the mul-
tivisceral recipients. 1 The failure to achieve higher survival 
rates could be related to the complexity of this unique 
population and our early learning experience. However, the 
immunobiologic effect of massive donor organ transplanta-
tion could be another contributing risk factor. In conclu-
sion, multivisceral transplantation is associated with satis-
factory long-term survival outcome and should be 
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selectively considered as a rescue therapy for patients with 
extensive gastrointestinal diseases. 
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